C-X-C motif chemokine ligand 12
C-X-C motif chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), is a chemokine protein that functions primarily through the C-X-C motif chemokine receptor 4 (CXCR4).
C-X-C motif chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), is a chemokine protein that functions primarily through the C-X-C motif chemokine receptor 4 (CXCR4). The CXCL12/CXCR4 signaling axis contributes to cellular recruitment, tissue remodeling, vascular responses, and communication between stromal, immune, endothelial, and tumor-associated cells. In the studies summarized here, CXCL12 was examined in ischemic brain injury, mesenchymal stem cell–associated neurogenesis, chronic obstructive pulmonary disease (COPD), mitral annulus calcification, hematological malignancies, and the tumor microenvironment.
The recent literature particularly connects CXCL12 with angiogenesis after ischemic stroke and with mitochondrial oxidative-stress-associated injury. It has also emerged as a molecular component of cancer-associated fibroblast programs and of the tumor microenvironment. Experimental assessments have included quantitative PCR, western blot, immunofluorescence, single-cell multi-omics, proteomic profiling, network toxicology, and machine-learning-based target prioritization. Related pathways and markers include NF-κB, matrix metalloproteinase-9 (MMP-9), aquaporin-4 (AQP4), vascular endothelial growth factor A (VEGFA), angiopoietins, and the CXCR4 receptor.
Rebuilt from PubMed 10 Sept 2026 · no new papers today
Where the papers sit
8 papers study c-x-c motif chemokine ligand 12 directly. Those 8 do not group into themes. Mechanistic preclinical work ranges from CXCL12/CXCR4-driven angiogenesis and metastasis to airway injury, wound repair, stroke recovery and vascular calcification, with no shared biological question or directional trajectory. They are no more alike than papers drawn from anywhere in the corpus.
Recent Findings on C-X-C motif chemokine ligand 12
Studies of ischemic injury converge on C-X-C motif chemokine ligand 12/C-X-C motif chemokine receptor 4 signaling as a modulator of post-stroke vascular and neural repair, although its effects depend on cellular context. In brain endothelial cells, the Astragaloside IV–tetramethylpyrazine combination enhanced migration and angiogenic marker expression, including vascular endothelial growth factor A and angiopoietin 1, in association with activation of the MALAT1–CXCL12/CXCR4 axis; MALAT1 knockdown impaired these responses 42655892Aug. By contrast, in an ischemia-reperfusion model, Nao-Xin-Tong Capsule improved perfusion and reduced edema, infarction, and astrocyte end-foot swelling while suppressing NF-κB-driven CXCL12/CXCR4 activation, linking excessive signaling to neuroinflammation and vascular hyperpermeability 42035998Apr. Work in chronic stroke monkeys extends the reparative direction of this research toward combination therapy, suggesting that mesenchymal stem cell transplantation plus intermittent theta-burst stimulation may enhance stem-cell chemotaxis and endogenous neurogenesis through increased CXCL12 secretion from transplanted cells 42031725Apr.
The mitochondrial oxidative-stress literature places C-X-C motif chemokine ligand 12 within broader, disease-specific signaling networks rather than establishing a single direct mitochondrial mechanism. In airway epithelial cells exposed to bisphenol A, CXCL12 was identified as one of several hub targets, while experimental protection against mitochondrial reactive oxygen species, loss of mitochondrial membrane potential, adenosine triphosphate depletion, structural damage, and reduced cell viability was demonstrated for NQO1 overexpression 42489718Jul. In triple-negative breast cancer, CXCL12 marked a myofibro-inflammatory cancer-associated fibroblast population enriched for epithelial–mesenchymal transition, PI3K/AKT, and TNF/NF-κB activity, with FOSB–HES1 implicated in fibroblast-state switching 42436124Jul. A complementary therapeutic strategy targeted C-X-C motif chemokine receptor 4 to block CXCL12-driven dissemination while deliberately generating reactive oxygen species with a platinum nanozyme, producing tumor killing and immune-microenvironment activation in hematological malignancy models 42086148May. Together, these studies are moving toward multi-omics-defined biomarkers and targeted interventions, but they do not show that CXCL12 itself mediates the mitochondrial injury or nanozyme-induced oxidative effects.
Proteomic profiling of rheumatic heart disease–related mitral annulus calcification identified CXCL12, SRC, and VCAM1 among core hub genes across calcified, thickened, and normal tissue states, situating CXCL12 within a coordinated pathway involving inflammation regulation, protein translation, and cell remodeling 42411643Jul. The study’s main advance was methodological as well as biological: magnetic carbon material–supported quasi-immobilized enzyme digestion enabled rapid processing and identification of 3,128 proteins from mitral valve tissues. These findings support CXCL12 as a candidate molecular target or biomarker for more precise diagnosis and targeted therapy of rheumatic heart disease complicated by mitral annulus calcification, but do not yet establish its causal role.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-08-28. Last written: 2026-08-29 by GPT. Drafted by language models from published abstracts; not medical advice.